Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQLNYSE:BHVNNASDAQ:EPZMNASDAQ:KRTXNASDAQ:RARX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQLArQule$20.00$20.00$3.15▼$20.45$2.42B2.495.27 million shsN/ABHVNBiohaven$14.63-0.9%$16.74$13.87▼$55.70$1.49B0.911.29 million shs753,892 shsEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsKRTXKaruna Therapeutics$329.83$327.01$158.38▼$329.99$12.58B1.18832,048 shs5 shsRARXRa Pharmaceuticals$47.99$47.99$19.64▼$48.02$2.27B1.051.16 million shs30,200 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQLArQule0.00%0.00%0.00%0.00%0.00%BHVNBiohaven0.00%+3.74%-9.75%-21.10%-56.70%EPZMEpizyme0.00%0.00%0.00%0.00%0.00%KRTXKaruna Therapeutics0.00%0.00%0.00%0.00%0.00%RARXRa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQLArQuleN/AN/AN/AN/AN/AN/AN/AN/ABHVNBiohaven3.4252 of 5 stars4.51.00.00.02.72.50.6EPZMEpizymeN/AN/AN/AN/AN/AN/AN/AN/AKRTXKaruna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARARXRa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQLArQule 0.00N/AN/AN/ABHVNBiohaven 3.07Buy$58.46299.60% UpsideEPZMEpizyme 0.00N/AN/AN/AKRTXKaruna Therapeutics 0.00N/AN/AN/ARARXRa Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BHVN, ARQL, KRTX, EPZM, and RARX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025BHVNBiohavenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.005/19/2025BHVNBiohavenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.005/13/2025BHVNBiohavenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025BHVNBiohavenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.004/28/2025BHVNBiohavenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $57.004/24/2025BHVNBiohavenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQLArQule$25.76M93.85N/AN/A$0.72 per share27.78BHVNBiohavenN/AN/AN/AN/A$4.19 per shareN/AEPZMEpizyme$37.43M6.61N/AN/A($0.54) per share-2.72KRTXKaruna Therapeutics$654K19,239.07N/AN/A$33.24 per share9.92RARXRa Pharmaceuticals$3M757.11N/AN/A$5.56 per share8.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQLArQule-$15.48M-$0.16N/AN/AN/A-805.61%-33.10%-26.87%N/ABHVNBiohaven-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)EPZMEpizyme-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/AKRTXKaruna Therapeutics-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/ARARXRa Pharmaceuticals-$102.69M-$2.31N/AN/AN/AN/A-44.61%-41.60%N/ALatest BHVN, ARQL, KRTX, EPZM, and RARX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BHVNBiohaven-$1.67-$2.17-$0.50-$2.17$1.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQLArQuleN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/AEPZMEpizymeN/AN/AN/AN/AN/AKRTXKaruna TherapeuticsN/AN/AN/AN/AN/ARARXRa PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQLArQule0.088.278.27BHVNBiohavenN/A2.332.33EPZMEpizymeN/A5.355.19KRTXKaruna TherapeuticsN/A19.3119.31RARXRa Pharmaceuticals0.0114.7814.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQLArQule74.63%BHVNBiohaven88.78%EPZMEpizyme76.45%KRTXKaruna TherapeuticsN/ARARXRa PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipARQLArQule13.80%BHVNBiohaven16.00%EPZMEpizyme23.40%KRTXKaruna Therapeutics13.20%RARXRa Pharmaceuticals4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQLArQule36120.87 millionN/AOptionableBHVNBiohaven239102.11 million85.78 millionOptionableEPZMEpizyme250168.33 million128.97 millionOptionableKRTXKaruna Therapeutics33938.15 million33.16 millionOptionableRARXRa Pharmaceuticals7247.33 millionN/AOptionableBHVN, ARQL, KRTX, EPZM, and RARX HeadlinesRecent News About These CompaniesAntibiotic Use Increases the Risk of Rheumatoid ArthritisOctober 13, 2024 | emjreviews.comETelix buys radiopharmacy network for $230M up front to expand US capacitySeptember 24, 2024 | endpts.comERheumatoid Arthritis and RA-ILD Linked to Increased Lung Cancer RiskSeptember 21, 2024 | rheumatologyadvisor.comRDeepCure links with Leeds Institute to bring AI-based RA drug to clinicAugust 20, 2024 | msn.comWhat Are the Treatment Options for Rheumatoid Arthritis?August 15, 2024 | healthline.comHTriple Therapy and TNF Inhibitor Treatments Differently Modify Lipid Profiles in RAAugust 9, 2024 | rheumatologyadvisor.comRRheumatoid Arthritis and RA-Associated Interstitial Lung Disease Linked to Higher Lung Cancer RiskAugust 9, 2024 | medscape.comMHigher Medication Adherence Linked to Reduced Adverse Outcomes in RAJuly 24, 2024 | rheumatologyadvisor.comRAbatacept Slows Atherosclerosis Progression Among High-Risk RA PatientsMay 28, 2024 | rheumatologyadvisor.comRDrug Insight: Tumor Necrosis Factor Converting Enzyme as a Pharmaceutical Target for Rheumatoid ArthritisFebruary 4, 2024 | medscape.comMRA: Discount Continues To Leave Some OpportunityJanuary 23, 2024 | seekingalpha.comFusion Pharma marks in-house radiopharma manufacturing success, details PhII/III trial studyJanuary 5, 2024 | endpts.comEAmon-Ra St. Brown pays off friendly wager he quips was made 'outside the facility'November 9, 2023 | freep.comFDetroit Lions game balls and goats: Amon-Ra St. Brown delivers; DBs need to be betterNovember 7, 2023 | freep.comFDetroit Lions No. 1 WR Amon-Ra St. Brown doubtful to play against Carolina PanthersOctober 27, 2023 | freep.comFImperial Petroleum, ARS Pharmaceuticals Stock, and More See Action From Activist InvestorsSeptember 8, 2023 | barrons.comAnthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public OfferingMay 29, 2023 | thestreet.comCourt rules for drugmakers in 340B fight over contract pharmaciesJanuary 31, 2023 | biopharmadive.comBUPDATE 1-AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln dealJanuary 10, 2023 | msn.comAstraZeneca to buy CinCor Pharma in $1.8 billion dealJanuary 9, 2023 | poandpo.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHVN, ARQL, KRTX, EPZM, and RARX Company DescriptionsArQule NASDAQ:ARQLArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer. Its pipeline also comprises ARQ 75, a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase or phosphatase, and tensin homolog loss mutations. In addition, the company's pipeline includes Derazantinib (ARQ 087), a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family of kinases that is in a registrational clinical trial in intrahepatic cholangiocarcinoma in patients with FGFR2 fusions. ArQule, Inc. has license agreements with Basilea Pharmaceutica Limited and Roivant Sciences Ltd. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.Biohaven NYSE:BHVN$14.63 -0.13 (-0.88%) Closing price 07/3/2025 03:30 PM EasternExtended Trading$14.66 +0.03 (+0.18%) As of 07/3/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Epizyme NASDAQ:EPZMEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Karuna Therapeutics NASDAQ:KRTXKaruna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Ra Pharmaceuticals NASDAQ:RARXRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
